Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Ashton, Nicholas J.; Janelidze, Shorena; Mattsson, Niklas; Binette, Alexa Pichet; Strandberg, Olof; Brum, Wagner S.; Karikari, Thomas K.; González‐Ortiz, Fernando; Molfetta, Guglielmo Di; Meda, Francisco J.; Jonaitis, Erin M.; Koscik, Rebecca L.; Cody, Karly Alex; Betthauser, Tobey J.; Li, Yan; Vanmechelen, Eugeen; Palmqvist, Sebastian; Stomrud, Erik; Bateman, Randall J.; Zetterberg, Henrik; Johnson, Sterling C.; Blennow, Kaj; Hansson, Oskar

doi:10.1038/s41591-022-02074-w

articleNature MedicineDec 1, 2022HYBRID OA

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

NJNicholas J. Ashton SJShorena Janelidze NMNiklas Mattsson APAlexa Pichet Binette OSOlof Strandberg

King's College London · Stavanger University Hospital · +15 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated…

Citation impact

424

total citations

FWCI: 44.82
Percentile: 100%
References: 57

Citations per year

Authors

23

Topics & keywords

Topics

Keywords

Medicine
Atrophy
Disease
Cohort
Cognitive decline
Biomarker
Alzheimer's disease
Pathology

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.